🔹 This increases the facility’s total capacity from 8,000L to 23,000L and improves manufacturing efficiency.
🔹 The bioreactors are expected to complete GMP release later this year.
🔹 WuXi Biologics aims to meet the needs of its clients by offering flexible, cost-effective, and sustainable services.
Introduction:
WuXi Biologics, a Contract Development and Manufacturing Organization (CRDMO), has installed three sets of 5,000L single-use bioreactors at its drug substance manufacturing facility in Hangzhou. The installation of these bioreactors will increase the facility’s total capacity from 8,000L to 23,000L, enhancing WuXi Biologics’ manufacturing capability for global clients.
- The installation of three 5,000L single-use bioreactors at WuXi Biologics’ Hangzhou facility will increase the facility’s capacity from 8,000L to 23,000L.
- The larger reactor size will improve manufacturing efficiency by reducing the number of production batches and lowering production costs.
- Single-use technologies are widely used across WuXi Biologics’ global manufacturing network, and the new bioreactors are expected to complete GMP release later this year.
- The addition of 5,000L single-use bioreactors is a significant milestone for WuXi Biologics, enhancing its capacity and capability to meet the needs of its clients.
- WuXi Biologics aims to offer more flexible, cost-effective, and sustainable services to advance therapies for patients worldwide.
Conclusion:
The installation of three 5,000L single-use bioreactors at WuXi Biologics’ Hangzhou facility will significantly increase the company’s manufacturing capacity and capability. This expansion will improve manufacturing efficiency, reduce costs, and allow WuXi Biologics to better meet the needs of its global clients. By utilizing single-use technologies and implementing innovative solutions, WuXi Biologics aims to provide flexible, cost-effective, and sustainable services to advance therapies for patients worldwide.
